The post 21Shares Seeks Injective ETF Amid Rising Institutional Demand appeared on BitcoinEthereumNews.com. 21Shares submits INJ ETF application, adding to its multiple product pipeline. Filing positions Injective among the few digital assets with multiple ETF offerings. Despite the ETF application, the coin’s price declined 4.5% in the last day. Exchange-traded product issuer 21Shares has filed an application for an Injective ETF and expanded the institutional investment vehicles available for the altcoin. The submission places INJ among a select group of digital assets attracting multiple ETF product developments. 21Shares ranks among the world’s largest exchange-traded product issuers with extensive experience in cryptocurrency investment vehicles. The company’s filing for INJ follows its track record of launching products for various digital assets. Injective stated the filing serves as a “major signal of growing institutional interest” in the protocol. The development positions INJ as one of the few altcoins progressing toward multiple ETF products simultaneously.  🚨 BREAKING: 21Shares just filed for a new $INJ ETF. This is a major signal of growing institutional interest, making $INJ one of the few digital assets with multiple ETF products in progress.@21Shares is among the world’s largest exchange traded product issuers. pic.twitter.com/xjWSZJVmsT — Injective 🥷 (@injective) October 20, 2025 Price Decline Contrasts With Institutional Development At press time, INJ is trading at $8.43, a decline of 4.5% over the past 24 hours despite the positive regulatory development. The token has declined 39% over the previous 30 days, showing price weakness during the filing period. Analyst Crypto Tony identified $9.70 as a potential safe entry point for bulls. Current price action suggests the market has not yet reacted positively to the ETF filing news. October 2025 has been characterized as “ETF month” by market analysts due to pivotal SEC decisions on numerous spot cryptocurrency ETF applications. The regulatory body implemented new generic listing standards, streamlining the approval process.  The updated framework reduces… The post 21Shares Seeks Injective ETF Amid Rising Institutional Demand appeared on BitcoinEthereumNews.com. 21Shares submits INJ ETF application, adding to its multiple product pipeline. Filing positions Injective among the few digital assets with multiple ETF offerings. Despite the ETF application, the coin’s price declined 4.5% in the last day. Exchange-traded product issuer 21Shares has filed an application for an Injective ETF and expanded the institutional investment vehicles available for the altcoin. The submission places INJ among a select group of digital assets attracting multiple ETF product developments. 21Shares ranks among the world’s largest exchange-traded product issuers with extensive experience in cryptocurrency investment vehicles. The company’s filing for INJ follows its track record of launching products for various digital assets. Injective stated the filing serves as a “major signal of growing institutional interest” in the protocol. The development positions INJ as one of the few altcoins progressing toward multiple ETF products simultaneously.  🚨 BREAKING: 21Shares just filed for a new $INJ ETF. This is a major signal of growing institutional interest, making $INJ one of the few digital assets with multiple ETF products in progress.@21Shares is among the world’s largest exchange traded product issuers. pic.twitter.com/xjWSZJVmsT — Injective 🥷 (@injective) October 20, 2025 Price Decline Contrasts With Institutional Development At press time, INJ is trading at $8.43, a decline of 4.5% over the past 24 hours despite the positive regulatory development. The token has declined 39% over the previous 30 days, showing price weakness during the filing period. Analyst Crypto Tony identified $9.70 as a potential safe entry point for bulls. Current price action suggests the market has not yet reacted positively to the ETF filing news. October 2025 has been characterized as “ETF month” by market analysts due to pivotal SEC decisions on numerous spot cryptocurrency ETF applications. The regulatory body implemented new generic listing standards, streamlining the approval process.  The updated framework reduces…

21Shares Seeks Injective ETF Amid Rising Institutional Demand

2025/10/22 03:41
3분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다
  • 21Shares submits INJ ETF application, adding to its multiple product pipeline.
  • Filing positions Injective among the few digital assets with multiple ETF offerings.
  • Despite the ETF application, the coin’s price declined 4.5% in the last day.

Exchange-traded product issuer 21Shares has filed an application for an Injective ETF and expanded the institutional investment vehicles available for the altcoin. The submission places INJ among a select group of digital assets attracting multiple ETF product developments.

21Shares ranks among the world’s largest exchange-traded product issuers with extensive experience in cryptocurrency investment vehicles. The company’s filing for INJ follows its track record of launching products for various digital assets.

Injective stated the filing serves as a “major signal of growing institutional interest” in the protocol. The development positions INJ as one of the few altcoins progressing toward multiple ETF products simultaneously. 

Price Decline Contrasts With Institutional Development

At press time, INJ is trading at $8.43, a decline of 4.5% over the past 24 hours despite the positive regulatory development. The token has declined 39% over the previous 30 days, showing price weakness during the filing period.

Analyst Crypto Tony identified $9.70 as a potential safe entry point for bulls. Current price action suggests the market has not yet reacted positively to the ETF filing news.

October 2025 has been characterized as “ETF month” by market analysts due to pivotal SEC decisions on numerous spot cryptocurrency ETF applications. The regulatory body implemented new generic listing standards, streamlining the approval process. 

The updated framework reduces approval timelines from up to 270 days to approximately 75 days for eligible products. This policy change removes many individualized reviews that previously extended evaluation periods.

Multiple altcoin ETF applications await decisions, including XRP, Solana, Litecoin, HBAR, and Cardano products. The new standards are expected to accelerate approvals for assets beyond Bitcoin and Ethereum.

Regulatory Environment Shifts Toward Broader Access

The recent U.S. government shutdown delayed SEC reviews of pending applications. With resolution expected this week, several long-pending filings are anticipated to advance rapidly through the approval process.

The generic listing standards establish precedent for Wall Street adoption of regulated digital asset products. Analysts project the policy will trigger increased launches of spot cryptocurrency ETFs across various tokens.

21Shares’ decision to file for INJ specifically indicates an assessment that the token meets requirements under the new framework. The filing joins a growing pipeline of altcoin ETF applications seeking regulatory approval during October’s concentrated decision period.

Related: https://coinedition.com/xrp-price-prediction-key-support-at-risk-as-security-scare-adds-to-etf-uncertainty/

Disclaimer: The information presented in this article is for informational and educational purposes only. The article does not constitute financial advice or advice of any kind. Coin Edition is not responsible for any losses incurred as a result of the utilization of content, products, or services mentioned. Readers are advised to exercise caution before taking any action related to the company.

Source: https://coinedition.com/21shares-files-inj-etf-as-injective-joins-elite-group-with-multiple-etf-bids/

시장 기회
Injective 로고
Injective 가격(INJ)
$3.39
$3.39$3.39
+1.22%
USD
Injective (INJ) 실시간 가격 차트
면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

USD1 Genesis: 0 Fees + 12% APR

USD1 Genesis: 0 Fees + 12% APRUSD1 Genesis: 0 Fees + 12% APR

New users: stake for up to 600% APR. Limited time!